
ALT WOW! Beam Therapeutics has announced positive topline results from its BEACON Phase 1/2 study aimed to evaluate ristoglogene autogetemcel (risto-cel) - formally known as BEAM - 101, in sickle cell disease patients (SCD) with severe vaso-occlusive crises (VOCs). Not only did Beam’s BEACON trial successfully achieved its primary efficacy endpoint - freedom from severe Vaso-occlusive Crises (VOCs) for at least 12 consecutive months, the trail also met all of its primary safety endpoints and secondary endpoints - including freedom from inpatient hospitalization for severe VOCs during a period of 12 consecutive months. These outstanding results supports Beam’s planned U.S. Biologics License Application (BLA) submission to the U.S FDA for risto-cel, which is expected as early as Year-End 2026 making it Beam’s first potential commercial product in the market.

































